Evofem
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Evofem sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Evofem: 6 sponsored US clinical trials, none currently recruiting.
Evofem sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Central Abdominal Bulging, with 1 trials.
Upper-quartile sponsor footprint
Evofem sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
NCT04553068
Phase 2B/3 Double-blinded Placebo-controlled
NCT03107377
AMP002 Phase III Contraceptive Study
NCT03243305
Duration of Effect of Acidform Gel on Vaginal pH
NCT02693418
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
NCT02398188
Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel
NCT01306331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 4 |
Therapeutic Areas
How the Evofem archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Central Abdominal Bulging (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Evofem: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Evofem sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Evofem page
6 registered trials is a research-attention snapshot, not an endorsement of Evofem or any single study.
- None of Evofem's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Central Abdominal Bulging is the condition Evofem studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Central Abdominal Bulging trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Evofem pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.